ClinicalTrials.gg
Not yet recruitingNCT07951762Updated Nov 20, 2026

A Phase I/II Clinical Trial of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in the Treatment of Advanced Solid Tumors.

A Phase 1/2 interventional study of SYS6043+PD-1/VEGF bispecific antibody and SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy. in Advanced Solid Tumor, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
368
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter phase 1/2 clinical study to evaluate the efficacy and safety of SYS6043 monotherapy or SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy in patients with advanced solid tumors.

Read the detailed description

The Phase I study is a a dose-escalation study, comprises dose escalation for the doublet regimen and dose escalation for the triplet regimen. The Phase II study isa cohort expansion study.

Phase I: the dose escalation use a 3+3 design. The doublet regimen consists of SYS6043 + PD-1/VEGF bispecific antibody. The triplet regimen consists of SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.

The Phase II study will be conducted as an expansion in 6 cohorts, with indications including triple-negative breast cancer, small cell lung cancer, non-small cell lung cancer, etc.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. is the lead sponsor of 43 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to understand and voluntarily sign and datethe written ICF prior to any trial-related procedure;
  2. Age 18-75 (inclusive) years;
  3. or cytologically confirmed advanced/unresectable or solid tumors(specific cohort requirements apply, including TNBC, SCLC, and driver-gene negative NSCLC based on UICC/AJCC 8th edition staging);
  4. Dose escalation phase: evaluable lesions per v1.1. Dose expansion phase: at least one extracranial per RECIST v1.1. Lesions previously treated with radiotherapy or other local therapy may not be selected as target lesions unless there is clear evidence of progression.
  5. Qualified archived or fresh tumor tissue samples must be provided; participants who cannot provide tumor samples or whose samples are insufficient may be enrolled based on individual circumstances.
  6. (ECOG) performance status score: 0-1;
  7. Adequate organ and bone marrow function within 7 days prior to the first dose, as defined below.
  8. ≥ 3 months;
  9. Female participants of childbearing age must have a negative serum pregnancy test within 7 days before dosing. Male and female participants of must agree to use adequate during the study and for at least 7 months after the last dose of the product; during this period, female participants must not be breastfeeding, male participants must not freeze or donate sperm, and female participants must not donate eggs or undergo egg retrieval for personal use.

Exclusion criteria

Exclusion Criteria:

  1. Combined SCLC (i.e., mixed large cell carcinoma, squamous cell carcinoma, spindle/pleomorphic and/or large cell components) and transformed SCLC.
  2. Prior history of grade ≥3 immune-related adverse events (irAEs) during treatment with anti-PD-(L)1 or other , immune checkpoint agonists, immune cell therapy, or other therapies targeting tumor immune mechanisms, except for endocrine disorders such as hyperglycemia or hypothyroidism that have recovered to grade ≤2.
  3. Prior treatment with B7-H3-targeted therapies (including antibodies, antibody-drug conjugates [ADCs], chimeric antigen receptor T-cell [CAR-T] therapies, and other agents).
  4. Prior treatment with a topoisomerase I inhibitor antibody-drug conjugate or a topoisomerase I inhibitor.
  5. Toxicities from prior antitumor therapy have not resolved to CTCAE grade ≤1 or to the levels specified in the inclusion/exclusion criteria (except alopecia and hyperpigmentation).
  6. History of underlying pulmonary disease, including but not limited to severe asthma, severe , restrictive lung disease, and other pulmonary impairment or requirement for supplemental oxygen.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
368 participants (estimated)

Study arms

  • Experimental
    SYS6043+PD-1/VEGF bispecific antibody

    Drug: SYS6043+PD-1/VEGF bispecific antibody

  • Experimental
    SYS6043 combined with PD-1/VEGF bispecific antibody +chemotherapy.

    Drug: SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.

  • Experimental
    SYS6043 monotherapy

    Drug: SYS6043 monotherapy

Interventions

  • DrugSYS6043+PD-1/VEGF bispecific antibody

    SYS6043: IV PD-1/VEGF bispecific antibody: IV

  • DrugSYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.

    SYS6043: IV PD-1/VEGF bispecific antibody: IV Chemotherapy: cisplatin or carboplatin, IV

  • DrugSYS6043 monotherapy

    SYS6043: IV

06

What researchers measure

Primary outcomes

  1. Phase I: Incidences of AEs

    Time frame: From the signing of the informed consent form until 90 days after the last dose.

  2. Phase I: DLT

    Dose-limiting toxicity

    Time frame: 21 days

  3. Phase I: MTD/RP2D

    Maximum Tolerated Dose/ Recommended Phase II Dose

    Time frame: After phase I dose escalation stage. Approximately 4 months.

  4. Phase II: ORR

    Objective response rate

    Time frame: Up to 2 years

Secondary outcomes

  1. Phase I: ORR

    Objective response rate

    Time frame: Up to 2 years

  2. Phase I:DCR

    Disease control rate

    Time frame: Up to 2 years

  3. Phase I:DOR

    Duration of response

    Time frame: Up to 2 years

  4. Phase I: TTR

    Time to Response

    Time frame: Up to 2 years

  5. Phase I: PFS

    Progression free survival

    Time frame: Up to 2 years

  6. Phase I:OS

    Overall survival

    Time frame: Up to 3 years

  7. Phase I:Plasma concentrations of SYS6043, total antibody, and free JS-1.

    Time frame: Up to 2 years

  8. Phase I:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.

    Time frame: Up to 2 years

  9. Phase I:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.

    Time frame: Up to 2 years

  10. Phase II:DCR

    Disease control rate

    Time frame: Up to 2 years

  11. Phase II:DOR

    Duration of response

    Time frame: Up to 2 years

  12. Phase II: TTR

    Time to Response

    Time frame: Up to 2 years

  13. Phase II: PFS

    Progression free survival

    Time frame: Up to 2 years

  14. Phase II:OS

    Time frame: Up to 3 years

  15. Title: Phase II: Incidences of AEs

    Overall survival

    Time frame: From the signing of the informed consent form until 90 days after the last dose.

  16. Phase II:Plasma concentrations of SYS6043, total antibody, and free JS-1.

    Time frame: Up to 2 years

  17. Phase II:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.

    Time frame: Up to 2 years

  18. Phase II:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.

    Time frame: Up to 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 20, 2026
StartEst.
Dec 30, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07951762
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Dec 30, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Jian Zhang
Contact
syner2000@163.com
021-64175590

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion